Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GH - Guardant Health Inc


IEX Last Trade
25.6
-0.330   -1.289%

Share volume: 2,498,853
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST

PREVIOUS CLOSE
CHG
CHG%

$25.93
-0.33
-1.27%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Company vs Stock growth
vs
Performance
5 Days
-11.85%
1 Month
-29.51%
3 Months
-6.88%
6 Months
36.57%
1 Year
-36.00%
2 Year
-46.95%
Key data
Stock price
$25.60
P/E Ratio 
-6.41
DAY RANGE
$25.27 - N/A
EPS 
-$4.08
52 WEEK RANGE
$15.81 - $37.66
52 WEEK CHANGE
-$0.27
MARKET CAP 
3.147 B
YIELD 
N/A
SHARES OUTSTANDING 
123.022 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,681,619
AVERAGE 30 VOLUME 
$2,629,177
Company detail
CEO: Helmy Eltoukhy
Region: US
Website: guardanthealth.com
Employees: 2,284
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.

Recent news